Biogena Group Invest: Capital Raise Nears End as €475 Million Valuation Shapes Merger Terms
Published on 07/20/2026 at 04:54 | Redaktion boerse-global.de
The restructuring clock is ticking for Biogena Group Invest. With the subscription window for Biogena Good Vibes AG’s capital increase closing on 22 July, the group has now put a concrete number on what it hopes will be the exchange ratio for the planned merger: €475 million. That valuation, published by the future parent company, provides the first hard figure for investors trying to gauge the terms of the consolidation.
The capital raise, which kicked off on 10 June, offers shares at €4.803 apiece and targets a gross proceeds of around €20 million. An expansion option could lift that total to €25 million. By the time the offer expires at midnight MESZ on 22 July, the market will have a clear read on demand for the holding-company equity — demand that will directly influence how the subsequent integration with the listed Group Invest AG plays out. Management has stressed that no binding decision on the timing, conditions or exchange ratio has been reached, but the €475 million figure now anchors the negotiation.
A fourfold revenue ambition
Alongside the merger arithmetic, Biogena Group Invest spelled out its long-term growth trajectory. The “Vision 2030” plan targets group-wide sales of €500 million by the end of the decade, starting from about €125 million in the 2024/25 financial year — a near-quadrupling of the top line. That ambition dovetails with the restructuring: a simplified structure under the Good Vibes AG umbrella is intended to free the group to chase those numbers. For the last reported year, the Salzburg-based micronutrient manufacturer generated roughly €124.9 million in revenue and an EBITDA of €19.1 million, giving it a solid operational base.
Should investors sell immediately? Or is it worth buying Biogena Group Invest?
Stock rally reflects investor focus
The share price has been tracking the restructuring story closely. On Friday, Biogena Group Invest closed at €4.70, up 3.52% on the day and just 2.08% shy of its recent 52-week high of €4.80. Year-to-date, the stock has surged 59.27%. Thin trading amplifies every piece of news from the reorganisation process — a dynamic that has been on full display in recent weeks as the valuation news and capital raise details filtered out.
Beyond the merger math, the company has kept its regular shareholder commitments intact. For 2025/26 it paid a €0.05 per share dividend (ex-date in April), and the annual general meeting in March approved the appropriation of retained earnings and granted discharge to the board and supervisory board. The audited full-year accounts for the end of January formed the basis for those resolutions.
What comes next for investors
Two events now dominate the calendar. The capital increase subscription window closes on 22 July. Then, on 27 August, the group will release its half-year results for 2026 — the first operational snapshot since the merger talks were announced — while simultaneously Biogena Good Vibes AG is slated to begin trading on the Vienna Stock Exchange. The coincidence of the two milestones will test whether the €475 million valuation and the 2030 revenue roadmap hold up under the scrutiny of the public market. For holders of Biogena Group Invest shares, the outcome of the capital raise is the first piece of the puzzle, and the August dual date the second.
Ad
Biogena Group Invest Stock: New Analysis - 20 July
Fresh Biogena Group Invest information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
